VivoSim Labs, Inc. (VIVS) News
Track canonical SquawkNews coverage tagged to VIVS, VivoSim Labs, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 8 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
VIVS - VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
VIVS - VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
NEWS | Sep 16, 2026, 12:05 PM UTC
L
VivoSim Labs to add rat liver model to NAMkind platform
VivoSim Labs plans to add a rat liver model to its NAMkind platform.
EQUITY | Sep 01, 2026, 12:05 PM UTC
L
SEC Filings: Multiple Companies
Multiple companies file with SEC
EQUITY | Aug 03, 2026, 09:28 AM UTC
L
VIVS Sees Volatility
VIVS experiences volatility
EQUITY | Jul 31, 2026, 11:24 AM UTC
H
Why Callan JMB Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
Shares of Callan JMB Inc (NASDAQ: CJMB ) rose sharply in pre-market trading following the announcement that Callan JMB signed a strategic partnership with Alabama State University to build an integrated pharmaceutical ma
MACRO | Jul 17, 2026, 08:48 AM UTC
H
Why Vivosim Labs Shares Are Rocketing on Wednesday?
VivoSim Labs, Inc. (NASDAQ: VIVS ) shares are up on Wednesday as the company disclosed a significant milestone payment from Eli Lilly and Company (NYSE: LLY ) and provided optimistic revenue guidance for FY2027. The stoc
RATES | Jul 15, 2026, 03:20 PM UTC
H
VivoSim Labs Anticipates 500% Revenue Growth In FY27; Receives $5M Milestone Payment From Eli Lilly
VivoSim Labs, Inc. (Nasdaq: VIVS ) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced revenue guidance for FY2027
EARNINGS | Jul 15, 2026, 12:09 PM UTC
H
VivoSim Labs To Present Data Demonstrating Its 3D Human Tissue Models In Two Presentations At The European Society Of Toxicology Annual Conf
The presentations collectively showcase the best-in-industry predictive power of VivoSim's proprietary AI-enabled NAMkind™ Liver and NAMkind™ GI platforms. In liver toxicology testing, across a set of compounds where ani
GEOPOLITICS | Jun 29, 2026, 12:10 PM UTC